TenNor Therapeutics

TenNor Therapeutics (Ticker: 6872 HK) develops therapies for bacterial infections and diseases associated with bacterial metabolism. Its pipeline includes seven programs. Rifaquizinone (TNP-2092 injection) is being developed for infections associated with medical implants and bloodstream-related infections. Rifasutenizol (TNP-2198) is being developed for H. pylori infection, bacterial vaginosis and C. difficile infection. The IPO consists entirely of primary shares and includes a 15% greenshoe option. Planned uses of proceeds include research and development, product capacity, brand promotion and business development, working capital, and strategic acquisitions.

The scheduled listing date on Hong Kong Stock Exchange was May 22, 2026. The proposed offering comprises 8,280,000 shares at an indicative price of HKD 75.70 per share. The base offering would represent HKD 626.80 million, approximately $79.87 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $500.00 million.

CITIC Securities (Hong Kong) and ABCI Capital are sponsors.